Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Revolution Medicines, Inc.RVMD · Entity 606 | Chief Operating Officer | September 16, 2026 | September 18, 2026 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | June 12, 2025 | June 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Revolution Medicines, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 154,571 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 76 · Balance 154,571 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 149,680 |
Reported balance
After 2026-09-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 4,891 · Balance 149,680 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 56,713 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 56,713 restricted stock units.
SANGAMO THERAPEUTICS, INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,650 |
Reported balance
After 2025-06-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 82,650 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. F2: Includes 6,251 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in one final installment on December 15, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11 | Direct | 50,000 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F3: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2: Includes 6,251 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in one final installment on December 15, 2025.
F3: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2022 Filed Nov 2, 2022 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 17,767 | $20.41 | $362,540.97 |
DisclosureSEC source: 0001567619-22-019061 · doc1.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 17,767 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: This transaction was executed in multiple trades in prices ranging from $20.22 to $20.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Held by Margaret A. Horn Revocable Living Trust. Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 21:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 17,768 | $20.15 | $357,968.34 |
DisclosureSEC source: 0001567619-22-018896 · doc1.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 35,534 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: This transaction was executed in multiple trades in prices ranging from $20.00 to $20.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Held by Margaret A. Horn Revocable Living Trust. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:17 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,267 | $19.04 | $24,126.97 |
DisclosureSEC source: 0001567619-22-017690 · doc1.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,512 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.9737 to $19.0337, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 43,325 RSUs. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 21:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,145 | $17.75 | $20,323.18 |
DisclosureSEC source: 0001567619-22-013251 · doc1.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,779 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 937 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2022. F3 · balance_after: Includes 46,688 RSUs. Read SEC document |
| March 17, 2022 Filed Mar 22, 2022 00:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 321 | $18.61 | $5,975.25 |
DisclosureSEC source: 0001567619-22-007327 · doc1.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,987 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.1805 to $18.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 50,050 RSUs. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 135,800 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001567619-22-006235 · doc1.xml · derivative · entry 3 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,800 Underlying: Common Stock · 135,800 shares Expires 2032-02-29 F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:26 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 38,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006235 · doc1.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,308 F2 · balance_after: Includes 50,988 Restricted Stock Units. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 491 | $24.41 | $11,985.31 |
DisclosureSEC source: 0001567619-21-022401 · doc1.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,508 F2 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F3 · balance_after: Includes 12,188 RSUs. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 23:46 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 479 | $30.02 | $14,379.58 |
DisclosureSEC source: 0001567619-21-017413 · doc1.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,999 F2 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F3 · balance_after: Includes 13,125 RSUs. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:18 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 464 | $34.13 | $15,835.30 |
DisclosureSEC source: 0001567619-21-012489 · doc1.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,478 F2 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F3 · price: This transaction was executed in multiple trades in prices ranging from $33.96 to $34.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2021. F5 · balance_after: Includes 14,063 RSUs. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:44 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001567619-21-005850 · doc1.xml · derivative · entry 3 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2031-03-03 F3 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:44 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-005850 · doc1.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,198 F2 · balance_after: Includes 15,000 Restricted Stock Units. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 00:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001567619-21-002502 · doc1.xml · derivative · entry 4 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,800 Underlying: Common Stock · 35,000 shares Expires 2029-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: This option is early exercisable. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from August 9, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 00:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 35,000 | $55.00 | $1,925,000.00 |
DisclosureSEC source: 0001567619-21-002502 · doc1.xml · nonDerivative · entry 3 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,198 F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 00:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 35,000 | $4.73 | $165,550.00 |
DisclosureSEC source: 0001567619-21-002502 · doc1.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · balance_after: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| October 02, 2020 Filed Oct 2, 2020 23:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 12,495 | $35.40 | $442,320.50 |
DisclosureSEC source: 0001567619-20-017529 · doc1.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 53,302 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $35.00 to $36.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Held by Margaret A. Horn Revocable Living Trust. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 23:01 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 57,505 | $35.01 | $2,013,169.54 |
DisclosureSEC source: 0001567619-20-017529 · doc1.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 65,797 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $35.00 to $35.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Held by Margaret A. Horn Revocable Living Trust. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:24 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 47,060 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004021 · doc1.xml · derivative · entry 1 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,060 Underlying: Common Stock · 47,060 shares Expires 2030-02-11 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/48 of the shares subject thereto on each monthly anniversary of February 12, 2020, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.